^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study
Published date:
09/22/2021
Excerpt:
Among the 170 patients who received futibatinib 20 mg QD, 10.6% experienced PRs, and 38.2% experienced SD...In the gastric cancer cohort, the ORR was 22.2% (95% CI, 2.8%–60.0%): PRs were seen in 2 of 9 patients, 1 with an FGFR2 amplification (DOR, 3.5 months) and the other with an FGFR3-TACC3 fusion (DOR, 5.4 months). Three patients experienced SD (including 2 patientswith unconfirmed PRs), and the DCR was 55.6% (95% CI, 21.2%–86.3%).
DOI:
10.1158/2159-8290.CD-21-0697
Trial ID:
